BAP1 Loss is an inclusion criterion in 3 clinical trials for malignant solid tumor, of which 3 are open and 0 are closed. Of the trials that contain BAP1 Loss and malignant solid tumor as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 1/phase 2 (1 open) [5].

BAP1 Loss is an inclusion criterion in 3 clinical trials for melanoma, of which 3 are open and 0 are closed. Of the trials that contain BAP1 Loss and melanoma as inclusion criteria, 3 are phase 2 (3 open) [5].

BAP1 Loss is an inclusion criterion in 2 clinical trials for malignant mesothelioma, of which 1 is open and 1 is closed. Of the trials that contain BAP1 Loss and malignant mesothelioma as inclusion criteria, 2 are phase 2 (1 open) [5].

BAP1 Loss is an inclusion criterion in 2 clinical trials for urothelial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain BAP1 Loss and urothelial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [5].

BAP1 Loss is an inclusion criterion in 1 clinical trial for bladder carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BAP1 Loss and bladder carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

BAP1 Loss is an inclusion criterion in 1 clinical trial for diffuse large B-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains BAP1 Loss and diffuse large B-cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [5].

BAP1 Loss is an inclusion criterion in 1 clinical trial for endometrial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BAP1 Loss and endometrial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

BAP1 Loss is an inclusion criterion in 1 clinical trial for lymphoma, of which 1 is open and 0 are closed. Of the trial that contains BAP1 Loss and lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

BAP1 Loss is an inclusion criterion in 1 clinical trial for malignant soft tissue neoplasm, of which 1 is open and 0 are closed. Of the trial that contains BAP1 Loss and malignant soft tissue neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

BAP1 Loss is an inclusion criterion in 1 clinical trial for mantle cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains BAP1 Loss and mantle cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [5].

BAP1 Loss is an inclusion criterion in 1 clinical trial for mature T-cell and NK-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains BAP1 Loss and mature T-cell and NK-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) [5].

BAP1 Loss is an inclusion criterion in 1 clinical trial for ovarian clear cell adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains BAP1 Loss and ovarian clear cell adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

BAP1 Loss is an inclusion criterion in 1 clinical trial for pancreatic adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains BAP1 Loss and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

BAP1 Loss is an inclusion criterion in 1 clinical trial for peritoneal mesothelioma, of which 1 is open and 0 are closed. Of the trial that contains BAP1 Loss and peritoneal mesothelioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

BAP1 Loss is an inclusion criterion in 1 clinical trial for pleural mesothelioma, of which 1 is open and 0 are closed. Of the trial that contains BAP1 Loss and pleural mesothelioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

BAP1 Loss is an inclusion criterion in 1 clinical trial for renal cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BAP1 Loss and renal cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

BAP1 Loss is an inclusion criterion in 1 clinical trial for small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BAP1 Loss and small cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].